CXCL17 is an endogenous inhibitor of CXCR4 via a novel mechanism of action
C. W. White, L. E. Kilpatrick, N. Dale, R. S. Abhayawardana, S. Dekkers, M. J. Stocks, K. D. Pfleger, S. J. Hill
This study identifies CXCL17 as an endogenous inhibitor of CXCR4 through a novel mechanism involving interaction with neuropillin-1 and glycosaminoglycan binders.
bioRxiv · Jul 5, 2021 · PreprintPharmacology & Toxicology